Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.